Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1693

1.

Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.

Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T.

AIDS. 2003 Jul;17 Suppl 3:S5-15.

PMID:
14565604
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
3.

Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7.

PMID:
17146376
4.

Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.

Walenda C, Kouakoussui A, Rouet F, Wemin L, Anaky MF, Msellati P.

J Trop Pediatr. 2009 Jun;55(3):170-6. doi: 10.1093/tropej/fmn106. Epub 2008 Dec 9.

PMID:
19066169
5.

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.

Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

Antivir Ther. 2003 Oct;8(5):385-93.

PMID:
14640385
6.

The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire's Drug Access Initiative.

Diomandé FV, Bissagnéné E, Nkengasong JN, Maurice C, Monga B, Laga M, Nolan ML.

AIDS. 2003 Jul;17 Suppl 3:S87-93.

PMID:
14565614
7.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
8.

Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S49-54.

PMID:
14565609
9.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
10.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
11.

Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.

Diabaté S, Alary M.

HIV Med. 2009 Nov;10(10):640-6. doi: 10.1111/j.1468-1293.2009.00736.x. Epub 2009 Jul 29.

12.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

13.
14.

Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.

AIDS. 2008 Sep 12;22(14):1815-20. doi: 10.1097/QAD.0b013e32830b8ab9.

PMID:
18753864
15.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA.

AIDS. 2000 Jul 28;14(11):1545-52.

PMID:
10983641
16.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

17.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
18.
19.

Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.

Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, Blanche S, Msellati P.

AIDS. 2004 Sep 24;18(14):1905-13.

PMID:
15353976
20.

Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.

Sabin CA, Yee TT, Devereux H, Griffioen A, Loveday C, Phillips AN, Lee CA.

AIDS. 2000 May 26;14(8):1001-7.

PMID:
10853982
Items per page

Supplemental Content

Write to the Help Desk